Boris Draznin
Concepts (590)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin | 99 | 2025 | 2507 | 4.040 |
Why?
| | Hyperglycemia | 12 | 2025 | 375 | 3.290 |
Why?
| | Diabetes Mellitus | 16 | 2025 | 1098 | 3.140 |
Why?
| | Insulin Resistance | 32 | 2013 | 1241 | 2.510 |
Why?
| | Phosphatidylinositol 3-Kinases | 17 | 2012 | 381 | 2.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 23 | 2006 | 253 | 1.980 |
Why?
| | Adipocytes | 13 | 2008 | 223 | 1.760 |
Why?
| | Receptor, Insulin | 26 | 2003 | 94 | 1.740 |
Why?
| | Blood Glucose | 27 | 2025 | 2330 | 1.680 |
Why?
| | Alkyl and Aryl Transferases | 14 | 2003 | 31 | 1.580 |
Why?
| | Hypoglycemic Agents | 17 | 2025 | 1389 | 1.580 |
Why?
| | Diabetes Mellitus, Type 2 | 18 | 2025 | 2584 | 1.570 |
Why?
| | Insulin, Long-Acting | 4 | 2020 | 65 | 1.400 |
Why?
| | Hyperinsulinism | 11 | 2009 | 113 | 1.230 |
Why?
| | Calcium | 21 | 2007 | 1184 | 1.060 |
Why?
| | Protein Prenylation | 11 | 2006 | 19 | 0.970 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2007 | 452 | 0.970 |
Why?
| | Adipose Tissue | 19 | 2007 | 653 | 0.900 |
Why?
| | Phosphorylation | 32 | 2013 | 1733 | 0.820 |
Why?
| | Insulin Receptor Substrate Proteins | 15 | 2013 | 55 | 0.790 |
Why?
| | Signal Transduction | 25 | 2012 | 5233 | 0.780 |
Why?
| | Muscle, Skeletal | 11 | 2012 | 1796 | 0.760 |
Why?
| | Rats | 69 | 2007 | 5614 | 0.750 |
Why?
| | Hospitalization | 6 | 2025 | 2434 | 0.740 |
Why?
| | Insulin Glargine | 4 | 2014 | 88 | 0.640 |
Why?
| | Cytosol | 16 | 1994 | 227 | 0.640 |
Why?
| | Obesity | 15 | 2013 | 3082 | 0.640 |
Why?
| | Monosaccharide Transport Proteins | 9 | 2003 | 56 | 0.630 |
Why?
| | Epidemics | 1 | 2021 | 98 | 0.610 |
Why?
| | Inpatients | 3 | 2013 | 546 | 0.590 |
Why?
| | Animals | 106 | 2013 | 38109 | 0.570 |
Why?
| | Glucose | 25 | 2006 | 1049 | 0.560 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 207 | 0.560 |
Why?
| | Proteins | 15 | 2001 | 1022 | 0.560 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2006 | 266 | 0.550 |
Why?
| | Enzyme Inhibitors | 13 | 2007 | 826 | 0.530 |
Why?
| | Dietary Fats | 5 | 2012 | 315 | 0.520 |
Why?
| | Platelet-Derived Growth Factor | 4 | 2003 | 90 | 0.520 |
Why?
| | Deoxyglucose | 10 | 2008 | 51 | 0.510 |
Why?
| | Endocrinology | 1 | 2018 | 77 | 0.500 |
Why?
| | 3T3-L1 Cells | 5 | 2008 | 36 | 0.490 |
Why?
| | Adiponectin | 4 | 2009 | 244 | 0.480 |
Why?
| | Diabetes Mellitus, Type 1 | 8 | 2020 | 3890 | 0.480 |
Why?
| | Insulin-Like Growth Factor I | 11 | 2005 | 319 | 0.470 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 80 | 0.470 |
Why?
| | Enteral Nutrition | 3 | 2013 | 216 | 0.460 |
Why?
| | Phosphoproteins | 10 | 2007 | 346 | 0.460 |
Why?
| | Protein Kinases | 3 | 2008 | 315 | 0.460 |
Why?
| | Somatostatin | 13 | 2001 | 52 | 0.450 |
Why?
| | Islets of Langerhans | 17 | 1991 | 833 | 0.440 |
Why?
| | Triglycerides | 3 | 2012 | 521 | 0.440 |
Why?
| | Farnesyltranstransferase | 11 | 2009 | 21 | 0.440 |
Why?
| | Insulin, Isophane | 2 | 2013 | 22 | 0.430 |
Why?
| | Academic Medical Centers | 1 | 2018 | 548 | 0.430 |
Why?
| | Growth Hormone | 8 | 2007 | 92 | 0.430 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2025 | 699 | 0.420 |
Why?
| | Patient Care Planning | 1 | 2016 | 170 | 0.420 |
Why?
| | Rats, Inbred Strains | 26 | 1992 | 321 | 0.420 |
Why?
| | 3T3 Cells | 13 | 2007 | 156 | 0.420 |
Why?
| | Phosphates | 3 | 2007 | 180 | 0.420 |
Why?
| | Dietary Carbohydrates | 3 | 2012 | 151 | 0.420 |
Why?
| | Glucocorticoids | 2 | 2016 | 535 | 0.420 |
Why?
| | Cells, Cultured | 25 | 2008 | 4155 | 0.410 |
Why?
| | Humans | 69 | 2025 | 144957 | 0.410 |
Why?
| | Guanosine Triphosphate | 12 | 2000 | 89 | 0.390 |
Why?
| | Medically Uninsured | 1 | 2014 | 129 | 0.390 |
Why?
| | Muscle Proteins | 4 | 2012 | 244 | 0.390 |
Why?
| | Kinetics | 24 | 2012 | 1629 | 0.380 |
Why?
| | Continuity of Patient Care | 2 | 2019 | 292 | 0.370 |
Why?
| | Liver | 15 | 2009 | 1888 | 0.370 |
Why?
| | Sirtuin 1 | 1 | 2012 | 34 | 0.360 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1563 | 0.360 |
Why?
| | Enzyme Activation | 10 | 2008 | 768 | 0.360 |
Why?
| | Biphasic Insulins | 1 | 2011 | 3 | 0.360 |
Why?
| | Muscles | 3 | 2004 | 333 | 0.360 |
Why?
| | Diabetes Mellitus, Experimental | 5 | 1992 | 198 | 0.360 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 3 | 2007 | 55 | 0.350 |
Why?
| | Insulin Lispro | 1 | 2011 | 42 | 0.350 |
Why?
| | Patient Preference | 1 | 2014 | 225 | 0.350 |
Why?
| | Cystic Fibrosis | 2 | 2012 | 1158 | 0.350 |
Why?
| | Cell Membrane | 18 | 2003 | 706 | 0.340 |
Why?
| | Decision Making | 2 | 2018 | 980 | 0.340 |
Why?
| | Methylprednisolone | 1 | 2011 | 64 | 0.330 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 191 | 0.330 |
Why?
| | Thiazolidinediones | 2 | 2008 | 139 | 0.330 |
Why?
| | Atherosclerosis | 4 | 2019 | 409 | 0.320 |
Why?
| | Patient Care Team | 1 | 2016 | 689 | 0.320 |
Why?
| | Patient Admission | 1 | 2012 | 218 | 0.320 |
Why?
| | Mice | 28 | 2009 | 18365 | 0.320 |
Why?
| | Phosphoprotein Phosphatases | 4 | 1995 | 65 | 0.320 |
Why?
| | Blotting, Western | 9 | 2012 | 1187 | 0.320 |
Why?
| | Hospitals | 2 | 2013 | 732 | 0.310 |
Why?
| | Receptors, Cell Surface | 12 | 1986 | 377 | 0.310 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2011 | 2032 | 0.310 |
Why?
| | Epidermal Growth Factor | 6 | 1998 | 171 | 0.310 |
Why?
| | Phosphoric Monoester Hydrolases | 4 | 1994 | 56 | 0.300 |
Why?
| | Pituitary Gland, Anterior | 5 | 1988 | 37 | 0.300 |
Why?
| | Biomarkers | 3 | 2020 | 4275 | 0.300 |
Why?
| | Medicaid | 1 | 2014 | 462 | 0.300 |
Why?
| | Male | 57 | 2025 | 72406 | 0.300 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2001 | 428 | 0.300 |
Why?
| | rhoA GTP-Binding Protein | 4 | 2003 | 76 | 0.290 |
Why?
| | Quality Improvement | 2 | 2018 | 1291 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 14 | 0.290 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2001 | 145 | 0.290 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 116 | 0.290 |
Why?
| | MAP Kinase Signaling System | 3 | 2006 | 311 | 0.290 |
Why?
| | Gene Expression Regulation, Enzymologic | 4 | 2005 | 269 | 0.290 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2008 | 12 | 0.290 |
Why?
| | DNA-Binding Proteins | 5 | 2004 | 1500 | 0.280 |
Why?
| | Cyclic AMP | 9 | 1993 | 209 | 0.280 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1997 | 168 | 0.280 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 965 | 0.270 |
Why?
| | Mitochondrial Diseases | 1 | 2008 | 93 | 0.270 |
Why?
| | Algorithms | 1 | 2016 | 1839 | 0.270 |
Why?
| | Transfection | 9 | 2008 | 940 | 0.270 |
Why?
| | Diabetic Angiopathies | 2 | 2007 | 263 | 0.260 |
Why?
| | Adult | 20 | 2025 | 40506 | 0.260 |
Why?
| | Leukocytes | 2 | 2006 | 295 | 0.260 |
Why?
| | Pregnancy Proteins | 2 | 2005 | 35 | 0.260 |
Why?
| | Androstadienes | 5 | 2008 | 76 | 0.250 |
Why?
| | Early Growth Response Protein 1 | 2 | 2006 | 32 | 0.250 |
Why?
| | Phosphoserine | 1 | 2006 | 27 | 0.250 |
Why?
| | src Homology Domains | 2 | 2003 | 35 | 0.240 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 62 | 0.240 |
Why?
| | Middle Aged | 18 | 2025 | 35928 | 0.240 |
Why?
| | Female | 31 | 2025 | 78376 | 0.240 |
Why?
| | Organophosphonates | 2 | 1997 | 97 | 0.240 |
Why?
| | Cytoplasmic Granules | 6 | 1986 | 74 | 0.240 |
Why?
| | Glyburide | 6 | 1988 | 31 | 0.240 |
Why?
| | Fasting | 7 | 2005 | 277 | 0.240 |
Why?
| | Food Deprivation | 1 | 2006 | 27 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1416 | 0.230 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 55 | 0.230 |
Why?
| | Mitogens | 3 | 2001 | 55 | 0.230 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 243 | 0.230 |
Why?
| | Fatty Acids | 2 | 2012 | 452 | 0.230 |
Why?
| | Drug Synergism | 6 | 2003 | 357 | 0.220 |
Why?
| | Transcription Factors | 5 | 2004 | 1742 | 0.220 |
Why?
| | Transferases | 4 | 1997 | 27 | 0.220 |
Why?
| | RNA, Messenger | 8 | 2006 | 2832 | 0.220 |
Why?
| | In Vitro Techniques | 15 | 2003 | 1048 | 0.220 |
Why?
| | Adaptor Proteins, Vesicular Transport | 3 | 2001 | 44 | 0.220 |
Why?
| | Cell Division | 5 | 2009 | 766 | 0.220 |
Why?
| | Diet, Reducing | 1 | 2005 | 91 | 0.220 |
Why?
| | Diabetes, Gestational | 2 | 2006 | 321 | 0.220 |
Why?
| | Protein Subunits | 4 | 2008 | 226 | 0.210 |
Why?
| | Diabetes Complications | 2 | 2019 | 223 | 0.210 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 48 | 0.210 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 38 | 0.210 |
Why?
| | Fetal Blood | 1 | 2006 | 342 | 0.210 |
Why?
| | Cell Line | 12 | 2008 | 2882 | 0.200 |
Why?
| | Protein Kinase C | 3 | 1996 | 252 | 0.200 |
Why?
| | ras Proteins | 2 | 2009 | 151 | 0.200 |
Why?
| | Lysophospholipids | 2 | 2001 | 77 | 0.200 |
Why?
| | Garlic | 1 | 2003 | 2 | 0.200 |
Why?
| | Sulfinic Acids | 1 | 2003 | 6 | 0.190 |
Why?
| | Up-Regulation | 1 | 2006 | 852 | 0.190 |
Why?
| | Cell Nucleus | 3 | 1995 | 619 | 0.190 |
Why?
| | Metabolic Syndrome | 3 | 2013 | 354 | 0.190 |
Why?
| | Aged | 10 | 2025 | 25947 | 0.180 |
Why?
| | Intensive Care Units | 2 | 2025 | 916 | 0.180 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 2 | 1992 | 56 | 0.170 |
Why?
| | Plant Extracts | 1 | 2003 | 187 | 0.170 |
Why?
| | Breast Neoplasms | 3 | 2003 | 2456 | 0.170 |
Why?
| | Caloric Restriction | 2 | 2012 | 127 | 0.170 |
Why?
| | Cell Cycle | 2 | 2001 | 597 | 0.160 |
Why?
| | Growth Substances | 2 | 1998 | 140 | 0.160 |
Why?
| | Angiotensin II | 1 | 2000 | 97 | 0.160 |
Why?
| | Nitrendipine | 7 | 1993 | 12 | 0.160 |
Why?
| | Cattle | 6 | 2007 | 1000 | 0.150 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 2 | 1996 | 49 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2609 | 0.150 |
Why?
| | Fetal Diseases | 1 | 2001 | 191 | 0.150 |
Why?
| | Deoxy Sugars | 2 | 1989 | 2 | 0.150 |
Why?
| | Oxidative Stress | 1 | 2006 | 1339 | 0.150 |
Why?
| | Weight Loss | 1 | 2005 | 837 | 0.150 |
Why?
| | Receptor, IGF Type 1 | 1 | 1998 | 64 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2021 | 285 | 0.140 |
Why?
| | GTP-Binding Proteins | 1 | 1999 | 153 | 0.140 |
Why?
| | Serine | 2 | 2008 | 145 | 0.130 |
Why?
| | Cations | 1 | 1998 | 82 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2003 | 292 | 0.130 |
Why?
| | Aging | 5 | 1992 | 1966 | 0.130 |
Why?
| | Receptors, Somatostatin | 11 | 1986 | 23 | 0.130 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 477 | 0.130 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 1996 | 168 | 0.130 |
Why?
| | Models, Organizational | 1 | 2018 | 144 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 357 | 0.130 |
Why?
| | NF-kappa B | 1 | 2000 | 662 | 0.120 |
Why?
| | Oncogene Protein v-akt | 2 | 2008 | 22 | 0.120 |
Why?
| | Young Adult | 6 | 2020 | 14126 | 0.120 |
Why?
| | Life Style | 1 | 2019 | 479 | 0.120 |
Why?
| | Pilot Projects | 2 | 2014 | 1890 | 0.120 |
Why?
| | Time Factors | 7 | 2006 | 7183 | 0.120 |
Why?
| | Exocytosis | 5 | 1988 | 84 | 0.120 |
Why?
| | Hypertension | 3 | 2019 | 1264 | 0.120 |
Why?
| | 1-Methyl-3-isobutylxanthine | 6 | 1986 | 24 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2021 | 693 | 0.120 |
Why?
| | Fibroblasts | 6 | 2001 | 1034 | 0.120 |
Why?
| | Potassium | 7 | 1992 | 152 | 0.120 |
Why?
| | Recombinant Proteins | 5 | 2001 | 1371 | 0.120 |
Why?
| | Swine, Miniature | 2 | 2013 | 89 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 983 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2016 | 17101 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 138 | 0.110 |
Why?
| | Calcium-Transporting ATPases | 2 | 1993 | 33 | 0.110 |
Why?
| | Mice, Obese | 2 | 2009 | 66 | 0.110 |
Why?
| | Somatomedins | 5 | 1981 | 28 | 0.110 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 164 | 0.110 |
Why?
| | Glycogen Synthase | 2 | 1991 | 6 | 0.110 |
Why?
| | Placenta Growth Factor | 2 | 2005 | 26 | 0.110 |
Why?
| | Prospective Studies | 4 | 2025 | 7997 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 5 | 2006 | 2540 | 0.100 |
Why?
| | Glucose Transporter Type 4 | 3 | 2003 | 38 | 0.100 |
Why?
| | Rats, Zucker | 2 | 2007 | 32 | 0.100 |
Why?
| | Thinness | 2 | 2012 | 99 | 0.100 |
Why?
| | Fatty Acid Synthases | 2 | 2006 | 23 | 0.100 |
Why?
| | Inulin | 1 | 1993 | 12 | 0.100 |
Why?
| | United States | 5 | 2021 | 15988 | 0.100 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 361 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2018 | 11695 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 289 | 0.100 |
Why?
| | Point-of-Care Systems | 1 | 2015 | 187 | 0.100 |
Why?
| | ras Guanine Nucleotide Exchange Factors | 5 | 1996 | 8 | 0.100 |
Why?
| | GRB2 Adaptor Protein | 5 | 2001 | 12 | 0.090 |
Why?
| | Guanosine Diphosphate | 4 | 1997 | 20 | 0.090 |
Why?
| | Education, Medical | 1 | 1996 | 276 | 0.090 |
Why?
| | Mice, Transgenic | 4 | 2007 | 2185 | 0.090 |
Why?
| | Insulin Antagonists | 2 | 2008 | 6 | 0.090 |
Why?
| | Guanine Nucleotide Exchange Factors | 5 | 1996 | 64 | 0.090 |
Why?
| | Cricetinae | 3 | 2001 | 304 | 0.090 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 164 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 105 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2018 | 853 | 0.090 |
Why?
| | Phospholipases A | 1 | 1991 | 98 | 0.090 |
Why?
| | ras GTPase-Activating Proteins | 3 | 1996 | 14 | 0.090 |
Why?
| | Models, Biological | 4 | 2007 | 1822 | 0.090 |
Why?
| | ErbB Receptors | 4 | 1996 | 629 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4293 | 0.090 |
Why?
| | PPAR gamma | 1 | 2012 | 177 | 0.080 |
Why?
| | Transcription, Genetic | 3 | 2012 | 1496 | 0.080 |
Why?
| | Isoenzymes | 1 | 1991 | 299 | 0.080 |
Why?
| | GTPase-Activating Proteins | 3 | 1996 | 82 | 0.080 |
Why?
| | Chromones | 2 | 2004 | 42 | 0.080 |
Why?
| | Flavonoids | 2 | 2004 | 87 | 0.080 |
Why?
| | Renal Insufficiency | 1 | 2013 | 169 | 0.080 |
Why?
| | Membrane Proteins | 2 | 1996 | 1167 | 0.080 |
Why?
| | Luciferases | 2 | 2000 | 152 | 0.080 |
Why?
| | Oncogene Protein p21(ras) | 3 | 1994 | 15 | 0.080 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1990 | 64 | 0.080 |
Why?
| | RNA | 2 | 2009 | 940 | 0.080 |
Why?
| | Reference Values | 5 | 2002 | 798 | 0.080 |
Why?
| | Morpholines | 2 | 2004 | 129 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2009 | 5997 | 0.080 |
Why?
| | Energy Metabolism | 3 | 2012 | 936 | 0.080 |
Why?
| | Genes | 1 | 1990 | 226 | 0.080 |
Why?
| | Genes, Reporter | 2 | 2000 | 276 | 0.080 |
Why?
| | Ion Channels | 2 | 1988 | 129 | 0.080 |
Why?
| | Diet | 3 | 2013 | 1275 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1099 | 0.070 |
Why?
| | Tyrosine | 2 | 2008 | 222 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2001 | 919 | 0.070 |
Why?
| | Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2008 | 5 | 0.070 |
Why?
| | Critical Illness | 1 | 2015 | 892 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 462 | 0.070 |
Why?
| | Cyclosporins | 1 | 1988 | 71 | 0.070 |
Why?
| | Aorta | 1 | 1991 | 430 | 0.070 |
Why?
| | CHO Cells | 2 | 2001 | 171 | 0.070 |
Why?
| | Cell Movement | 2 | 2003 | 965 | 0.070 |
Why?
| | Telemedicine | 1 | 2018 | 948 | 0.070 |
Why?
| | Verapamil | 4 | 1988 | 37 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2012 | 528 | 0.070 |
Why?
| | Biological Transport | 3 | 1998 | 418 | 0.070 |
Why?
| | Erectile Dysfunction | 1 | 1988 | 38 | 0.070 |
Why?
| | Patient Readmission | 1 | 2014 | 759 | 0.070 |
Why?
| | Liver Glycogen | 3 | 1986 | 15 | 0.070 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 336 | 0.070 |
Why?
| | Calcium Channels | 1 | 1988 | 154 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8279 | 0.070 |
Why?
| | PPAR alpha | 1 | 2007 | 54 | 0.070 |
Why?
| | Fenofibrate | 1 | 2007 | 28 | 0.070 |
Why?
| | Mevalonic Acid | 2 | 1997 | 12 | 0.070 |
Why?
| | Parathyroid Hormone | 3 | 1993 | 112 | 0.070 |
Why?
| | Lovastatin | 3 | 1996 | 37 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 26 | 0.060 |
Why?
| | Swine | 3 | 2013 | 833 | 0.060 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.060 |
Why?
| | Farnesol | 2 | 1997 | 5 | 0.060 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2013 | 204 | 0.060 |
Why?
| | Gene Expression | 1 | 2012 | 1490 | 0.060 |
Why?
| | Patient Discharge | 1 | 2014 | 983 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3415 | 0.060 |
Why?
| | Eating | 1 | 1990 | 392 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2009 | 283 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2001 | 675 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2007 | 88 | 0.060 |
Why?
| | Prostheses and Implants | 1 | 1988 | 141 | 0.060 |
Why?
| | Cell Fusion | 1 | 1986 | 49 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 1996 | 45 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2011 | 477 | 0.060 |
Why?
| | Bucladesine | 3 | 1992 | 19 | 0.060 |
Why?
| | Adenosine Triphosphate | 3 | 1993 | 498 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 313 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 16 | 0.060 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 635 | 0.060 |
Why?
| | Organophosphorus Compounds | 2 | 1997 | 85 | 0.060 |
Why?
| | Microscopy, Electron | 4 | 1989 | 415 | 0.060 |
Why?
| | Coated Pits, Cell-Membrane | 1 | 1985 | 3 | 0.060 |
Why?
| | Macromolecular Substances | 3 | 1996 | 224 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2005 | 3125 | 0.060 |
Why?
| | Heart | 1 | 2009 | 636 | 0.060 |
Why?
| | Interleukin-1 | 1 | 1989 | 961 | 0.060 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 3 | 2001 | 10 | 0.060 |
Why?
| | Shc Signaling Adaptor Proteins | 3 | 2001 | 10 | 0.060 |
Why?
| | Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2006 | 191 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2008 | 451 | 0.060 |
Why?
| | Theophylline | 1 | 1985 | 41 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 175 | 0.060 |
Why?
| | Body Weight | 6 | 2002 | 978 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 266 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1721 | 0.050 |
Why?
| | Basal Metabolism | 1 | 2005 | 63 | 0.050 |
Why?
| | Peptides | 2 | 1981 | 998 | 0.050 |
Why?
| | Risk | 1 | 2007 | 911 | 0.050 |
Why?
| | Hemodynamics | 1 | 2009 | 1121 | 0.050 |
Why?
| | Endosomes | 1 | 1985 | 140 | 0.050 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 10 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 3 | 1993 | 433 | 0.050 |
Why?
| | Blotting, Northern | 3 | 1995 | 204 | 0.050 |
Why?
| | Colorado | 1 | 2014 | 4564 | 0.050 |
Why?
| | Arachidonic Acids | 3 | 1988 | 43 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 1990 | 962 | 0.050 |
Why?
| | Phosphorus Radioisotopes | 2 | 1993 | 26 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 2 | 1996 | 623 | 0.050 |
Why?
| | Breast | 1 | 2003 | 159 | 0.050 |
Why?
| | Energy Intake | 2 | 2005 | 500 | 0.050 |
Why?
| | Hypothyroidism | 2 | 1980 | 67 | 0.050 |
Why?
| | Pregnancy | 3 | 2006 | 7191 | 0.050 |
Why?
| | Streptozocin | 2 | 1992 | 21 | 0.050 |
Why?
| | Placental Hormones | 1 | 2002 | 4 | 0.050 |
Why?
| | Cyclin D | 1 | 2001 | 8 | 0.040 |
Why?
| | Cyclin E | 1 | 2001 | 23 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2003 | 356 | 0.040 |
Why?
| | Carrier Proteins | 3 | 1980 | 737 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 862 | 0.040 |
Why?
| | Fetal Weight | 1 | 2001 | 54 | 0.040 |
Why?
| | Cyclins | 1 | 2001 | 84 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2001 | 2050 | 0.040 |
Why?
| | Starvation | 1 | 1981 | 23 | 0.040 |
Why?
| | Colforsin | 3 | 1991 | 48 | 0.040 |
Why?
| | Disease Models, Animal | 4 | 2013 | 4569 | 0.040 |
Why?
| | Nitric Oxide Synthase | 1 | 2001 | 235 | 0.040 |
Why?
| | Calmodulin | 3 | 1986 | 70 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2000 | 383 | 0.040 |
Why?
| | Serum Response Factor | 1 | 2000 | 33 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2003 | 457 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 123 | 0.040 |
Why?
| | Glucosamine | 1 | 2000 | 14 | 0.040 |
Why?
| | Response Elements | 1 | 2000 | 89 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 1 | 2001 | 169 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2001 | 423 | 0.040 |
Why?
| | Lysosomes | 1 | 1981 | 128 | 0.040 |
Why?
| | Hypopituitarism | 1 | 1980 | 16 | 0.040 |
Why?
| | Adenoviridae | 1 | 2001 | 199 | 0.040 |
Why?
| | Son of Sevenless Proteins | 2 | 1996 | 4 | 0.040 |
Why?
| | Glycation End Products, Advanced | 1 | 2000 | 82 | 0.040 |
Why?
| | Fura-2 | 2 | 1991 | 10 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2000 | 299 | 0.040 |
Why?
| | Leptin | 1 | 2001 | 245 | 0.040 |
Why?
| | Arachidonic Acid | 3 | 1988 | 101 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 210 | 0.040 |
Why?
| | DNA Replication | 1 | 2001 | 251 | 0.040 |
Why?
| | Disease Progression | 1 | 2007 | 2852 | 0.040 |
Why?
| | Muscle Denervation | 1 | 1999 | 8 | 0.040 |
Why?
| | Aurothioglucose | 1 | 1999 | 3 | 0.040 |
Why?
| | Endocrinologists | 1 | 2019 | 11 | 0.040 |
Why?
| | Clenbuterol | 1 | 1999 | 3 | 0.040 |
Why?
| | rab3 GTP-Binding Proteins | 1 | 1999 | 4 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 1999 | 7 | 0.040 |
Why?
| | Critical Care | 1 | 2025 | 697 | 0.040 |
Why?
| | Body Composition | 3 | 2009 | 706 | 0.040 |
Why?
| | Ionomycin | 2 | 1989 | 22 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2009 | 158 | 0.040 |
Why?
| | Dogs | 1 | 2000 | 438 | 0.040 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 1998 | 80 | 0.040 |
Why?
| | Endothelial Growth Factors | 1 | 1998 | 64 | 0.040 |
Why?
| | Sheep | 1 | 2001 | 880 | 0.040 |
Why?
| | Lymphokines | 1 | 1998 | 130 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2019 | 122 | 0.030 |
Why?
| | Diabetic Neuropathies | 1 | 2019 | 100 | 0.030 |
Why?
| | Protein Phosphatase 2 | 2 | 1995 | 41 | 0.030 |
Why?
| | Ethanol | 1 | 1983 | 627 | 0.030 |
Why?
| | Binding Sites | 2 | 1996 | 1331 | 0.030 |
Why?
| | Prosencephalon | 2 | 1994 | 53 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 477 | 0.030 |
Why?
| | Half-Life | 1 | 1997 | 151 | 0.030 |
Why?
| | Magnesium | 1 | 1998 | 155 | 0.030 |
Why?
| | Physician's Role | 1 | 2019 | 220 | 0.030 |
Why?
| | Dinitrophenols | 3 | 1982 | 7 | 0.030 |
Why?
| | Rats, Wistar | 1 | 1998 | 451 | 0.030 |
Why?
| | Growth Hormone-Releasing Hormone | 2 | 1988 | 19 | 0.030 |
Why?
| | Phenytoin | 1 | 1977 | 21 | 0.030 |
Why?
| | Fetus | 1 | 2001 | 803 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1996 | 10 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2019 | 208 | 0.030 |
Why?
| | Immunosorbent Techniques | 1 | 1996 | 18 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1996 | 22 | 0.030 |
Why?
| | Protein Phosphatase 1 | 2 | 1993 | 32 | 0.030 |
Why?
| | Second Messenger Systems | 1 | 1996 | 31 | 0.030 |
Why?
| | Oxygen Consumption | 2 | 2009 | 724 | 0.030 |
Why?
| | Body Mass Index | 1 | 2005 | 2438 | 0.030 |
Why?
| | Accidental Falls | 1 | 2019 | 222 | 0.030 |
Why?
| | Prediabetic State | 1 | 2019 | 245 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 128 | 0.030 |
Why?
| | Research Support as Topic | 1 | 1996 | 80 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 1998 | 557 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 1986 | 268 | 0.030 |
Why?
| | Immunoblotting | 1 | 1996 | 300 | 0.030 |
Why?
| | Genes, Immediate-Early | 1 | 1995 | 26 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2000 | 749 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 318 | 0.030 |
Why?
| | Immediate-Early Proteins | 1 | 1995 | 48 | 0.030 |
Why?
| | Off-Label Use | 1 | 2015 | 51 | 0.030 |
Why?
| | Glycogen | 1 | 1995 | 54 | 0.030 |
Why?
| | Phenotype | 1 | 2003 | 3164 | 0.030 |
Why?
| | Trypsin | 2 | 1993 | 76 | 0.030 |
Why?
| | Neurons | 2 | 1994 | 1642 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 647 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2006 | 6434 | 0.030 |
Why?
| | Peptide Mapping | 1 | 1994 | 63 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1995 | 193 | 0.030 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 1994 | 14 | 0.030 |
Why?
| | DNA | 2 | 1998 | 1464 | 0.030 |
Why?
| | ras-GRF1 | 1 | 1993 | 2 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2884 | 0.030 |
Why?
| | Chloroquine | 2 | 1986 | 53 | 0.020 |
Why?
| | Intracellular Membranes | 2 | 1985 | 76 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 280 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 489 | 0.020 |
Why?
| | Carbon Radioisotopes | 1 | 1993 | 29 | 0.020 |
Why?
| | Thapsigargin | 1 | 1993 | 20 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 1996 | 460 | 0.020 |
Why?
| | Thionucleotides | 1 | 1993 | 35 | 0.020 |
Why?
| | Terpenes | 1 | 1993 | 25 | 0.020 |
Why?
| | Mutation | 1 | 2004 | 4099 | 0.020 |
Why?
| | Phenols | 1 | 1993 | 114 | 0.020 |
Why?
| | Hormones | 2 | 1984 | 134 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 381 | 0.020 |
Why?
| | Research | 1 | 1996 | 431 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 2157 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1996 | 439 | 0.020 |
Why?
| | Blood Pressure | 2 | 2009 | 1769 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 653 | 0.020 |
Why?
| | Phosphorylase a | 1 | 1992 | 1 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1996 | 699 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 199 | 0.020 |
Why?
| | Okadaic Acid | 1 | 1991 | 15 | 0.020 |
Why?
| | Ethers, Cyclic | 1 | 1991 | 11 | 0.020 |
Why?
| | Vanadates | 1 | 1991 | 17 | 0.020 |
Why?
| | Mesocricetus | 1 | 1991 | 46 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 1991 | 79 | 0.020 |
Why?
| | Cadaverine | 2 | 1982 | 2 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1992 | 153 | 0.020 |
Why?
| | Densitometry | 1 | 1991 | 38 | 0.020 |
Why?
| | Calorimetry | 1 | 2012 | 72 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 1991 | 140 | 0.020 |
Why?
| | Wheat Germ Agglutinins | 1 | 1991 | 2 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 136 | 0.020 |
Why?
| | Arteries | 1 | 2013 | 259 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 331 | 0.020 |
Why?
| | Sodium | 1 | 1992 | 197 | 0.020 |
Why?
| | Sodium Fluoride | 2 | 1981 | 15 | 0.020 |
Why?
| | Food | 1 | 1992 | 149 | 0.020 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 13 | 0.020 |
Why?
| | Membrane Potentials | 1 | 1991 | 280 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 59 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1348 | 0.020 |
Why?
| | Japan | 1 | 1990 | 143 | 0.020 |
Why?
| | Secretory Rate | 2 | 1987 | 12 | 0.020 |
Why?
| | Homozygote | 1 | 1990 | 199 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 523 | 0.020 |
Why?
| | Sphingosine | 1 | 1989 | 45 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 45 | 0.020 |
Why?
| | Plethysmography | 1 | 2009 | 109 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1054 | 0.020 |
Why?
| | Trifluoperazine | 2 | 1987 | 3 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 124 | 0.020 |
Why?
| | Freeze Fracturing | 1 | 1988 | 4 | 0.020 |
Why?
| | Hydrostatic Pressure | 1 | 1988 | 30 | 0.020 |
Why?
| | Puberty | 1 | 2009 | 140 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 1087 | 0.020 |
Why?
| | Freezing | 1 | 1988 | 86 | 0.020 |
Why?
| | Ethers | 1 | 1987 | 19 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 413 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2009 | 358 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 5872 | 0.020 |
Why?
| | Egtazic Acid | 1 | 1987 | 38 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 437 | 0.020 |
Why?
| | Benzofurans | 1 | 1987 | 26 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 417 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 854 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 1987 | 168 | 0.020 |
Why?
| | Digitonin | 1 | 1986 | 5 | 0.020 |
Why?
| | Culture Techniques | 1 | 1986 | 67 | 0.010 |
Why?
| | Exercise Test | 1 | 2009 | 634 | 0.010 |
Why?
| | Echocardiography | 1 | 2009 | 652 | 0.010 |
Why?
| | Glyceraldehyde | 1 | 1985 | 2 | 0.010 |
Why?
| | DNA Primers | 1 | 2007 | 512 | 0.010 |
Why?
| | Pronase | 1 | 1985 | 5 | 0.010 |
Why?
| | Cell Membrane Permeability | 1 | 1986 | 85 | 0.010 |
Why?
| | Sonication | 1 | 1985 | 12 | 0.010 |
Why?
| | Heart Failure | 1 | 2019 | 2323 | 0.010 |
Why?
| | Adolescent | 4 | 2009 | 22453 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1985 | 53 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1987 | 330 | 0.010 |
Why?
| | Golgi Apparatus | 1 | 1985 | 100 | 0.010 |
Why?
| | Biopsy | 1 | 1988 | 1077 | 0.010 |
Why?
| | Urea | 1 | 1985 | 84 | 0.010 |
Why?
| | Peptide Hydrolases | 1 | 1986 | 105 | 0.010 |
Why?
| | Feedback | 1 | 1986 | 181 | 0.010 |
Why?
| | Heart Rate | 1 | 2009 | 855 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1985 | 193 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2009 | 780 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1985 | 334 | 0.010 |
Why?
| | Homeostasis | 1 | 1988 | 640 | 0.010 |
Why?
| | Gold | 1 | 1985 | 116 | 0.010 |
Why?
| | Motor Activity | 1 | 2009 | 722 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2171 | 0.010 |
Why?
| | Lipids | 1 | 2009 | 710 | 0.010 |
Why?
| | Chick Embryo | 2 | 1994 | 132 | 0.010 |
Why?
| | Organoids | 1 | 1986 | 141 | 0.010 |
Why?
| | Thyroxine | 2 | 1981 | 64 | 0.010 |
Why?
| | Endocytosis | 1 | 1984 | 168 | 0.010 |
Why?
| | 2,4-Dinitrophenol | 1 | 1982 | 9 | 0.010 |
Why?
| | Colchicine | 1 | 1982 | 21 | 0.010 |
Why?
| | Cycloheximide | 1 | 1982 | 46 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1982 | 69 | 0.010 |
Why?
| | Perfusion | 2 | 1981 | 250 | 0.010 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 25 | 0.010 |
Why?
| | Deuterium | 1 | 1982 | 100 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3608 | 0.010 |
Why?
| | Receptors, Somatomedin | 1 | 1981 | 5 | 0.010 |
Why?
| | Nutrition Disorders | 1 | 1981 | 20 | 0.010 |
Why?
| | Purine Nucleotides | 1 | 1981 | 12 | 0.010 |
Why?
| | Intracellular Fluid | 1 | 1981 | 25 | 0.010 |
Why?
| | Radioisotopes | 1 | 1981 | 37 | 0.010 |
Why?
| | Biotransformation | 1 | 1981 | 63 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 1980 | 84 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 1980 | 86 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1981 | 561 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1980 | 284 | 0.010 |
Why?
| | Growth Disorders | 1 | 1979 | 86 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 1988 | 5417 | 0.010 |
Why?
| | Inflammation | 1 | 2009 | 2880 | 0.010 |
Why?
| | 11-Hydroxycorticosteroids | 1 | 1977 | 1 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1996 | 39 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1995 | 35 | 0.010 |
Why?
| | Genes, fos | 1 | 1995 | 37 | 0.010 |
Why?
| | Child | 2 | 2009 | 22657 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1981 | 598 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 570 | 0.010 |
Why?
| | Neurites | 1 | 1994 | 50 | 0.010 |
Why?
| | Microinjections | 1 | 1994 | 92 | 0.010 |
Why?
| | Protein Binding | 1 | 1980 | 2276 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1994 | 196 | 0.010 |
Why?
| | Antibodies | 1 | 1994 | 403 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 2191 | 0.010 |
Why?
| | Cell Survival | 1 | 1994 | 1098 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 2931 | 0.010 |
Why?
| | Hydroxymercuribenzoates | 1 | 1987 | 1 | 0.000 |
Why?
| | Dantrolene | 1 | 1987 | 5 | 0.000 |
Why?
| | Oleic Acids | 1 | 1987 | 12 | 0.000 |
Why?
| | Lipoxygenase Inhibitors | 1 | 1987 | 34 | 0.000 |
Why?
| | Oleic Acid | 1 | 1987 | 42 | 0.000 |
Why?
| | Child, Preschool | 1 | 1980 | 11799 | 0.000 |
Why?
| | Membrane Fluidity | 1 | 1984 | 8 | 0.000 |
Why?
| | Diterpenes | 1 | 1984 | 26 | 0.000 |
Why?
| | Membrane Lipids | 1 | 1984 | 83 | 0.000 |
Why?
| | Glucagon | 1 | 1984 | 113 | 0.000 |
Why?
| | Adenine Nucleotides | 1 | 1982 | 21 | 0.000 |
Why?
| | Phospholipids | 1 | 1984 | 213 | 0.000 |
Why?
| | Adenosine Triphosphatases | 1 | 1982 | 162 | 0.000 |
Why?
| | Nephrectomy | 1 | 1981 | 158 | 0.000 |
Why?
| | Propylthiouracil | 1 | 1979 | 6 | 0.000 |
Why?
| | Hypophysectomy | 1 | 1979 | 15 | 0.000 |
Why?
| | Puromycin | 1 | 1979 | 10 | 0.000 |
Why?
| | Radioligand Assay | 1 | 1979 | 37 | 0.000 |
Why?
| | Kidney | 1 | 1981 | 1496 | 0.000 |
Why?
|
|
Draznin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|